MUTABILIS
Mutabilis is discovery of new therapeutic targets for the development of anti-infectives. Mutabilis is a biopharmaceutical company specialised in the discovery and development of anti-infectives. Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and targeting severe bacterial infections. Mutabilis’ new therapies target nosocomial infections in particular.
MUTABILIS
Industry:
Biotechnology
Founded:
2001-01-01
Address:
Paris, Ile-de-France, France
Country:
France
Website Url:
http://www.en.mutabilis.fr
Total Employee:
11+
Status:
Active
Contact:
+33 1 57 14 05 20
Total Funding:
14.24 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API LetsEncrypt WordPress Font Awesome Domain Not Resolving Apache
Similar Organizations
Affimed
Affimed Therapeutics is focused on developing recombinant antibody therapeutics for the treatment of cancer and other diseases.
Excision BioTherapeutics
Excision is developing CRISPR-based therapies to cure viral infectious diseases and improve the lives of chronically ill patients.
PIQUR Therapeutics
PIQUR Therapeutics is a Swiss pharmaceutical company focusing on the discovery and development of anti-cancer drugs.
Spero Therapeutics
Spero Therapeutics develops therapeutics for treatment of gram-negative infections.
Current Employees Featured
Founder
Investors List
CARB-X
CARB-X investment in Grant - Mutabilis
Repair Impact Fund
Repair Impact Fund investment in Venture Round - Mutabilis
Omnes Capital
Omnes Capital investment in Venture Round - Mutabilis
More informations about "Mutabilis"
Mutabilis
Mutabilis is a biopharmaceutical company developing novel-class antibacterials to treat life-threatening infection caused by WHO Priority 1 / Critical pathogens: Carbapenem-resistant …See details»
Mutabilis - Crunchbase Company Profile & Funding
Mutabilis discovers and develops innovative anti-infectives, a novel class of drug addressing the current issues arising from resistance to antibiotics and …See details»
CARB-X is funding French biotech Mutabilis to develop a new …
(BOSTON: February 3, 2021) – CARB-X is awarding Mutabilis, a biopharmaceutical firm based in Romainville, France, up to US$6.4 million to develop a new drug to treat infections caused by …See details»
Mutabilis S.A. - Life-Sciences-Europe.com
Jan 1, 2001 · Mutabilis is a spin-off from INSERM that was created in August 2001 and is specialized in the discovery of new therapeutic approaches for treating bacterial infections. Its …See details»
Mutabilis, France - AMR Industry Alliance
The AMR Industry Alliance brings together biotech, diagnostics, generics and research-based pharmaceutical companies, to drive and measure industry progress to curb antimicrobial …See details»
Mutabilis Company Profile 2024: Valuation, Investors, …
Information on acquisition, funding, investors, and executives for Mutabilis. Use the PitchBook Platform to explore the full profile.See details»
Mutabilis joins the European ENABLE consortium to fight antibiotic ...
Oct 17, 2017 · Biocitech, Paris, France, October 17, 2017 – Mutabilis, a company specialized in the discovery of new therapeutic approaches to treat resistant bacterial infections, today …See details»
Mutabilis - REPAIR Impact Fund
Mutabilis is a biotechnology company focused on the development of novel chemical entities to treat MDR Gram-negative bacterial infections. Mutabilis’ team has a unique expertise in …See details»
Mutabilis - LinkedIn
New Antibiotics against Multi Resistant Gram-negative bacterial infections | Mutabilis is a privately-held French biopharmaceutical company developing novel non-beta-lactam PBP-targeting antibacterial drugs called dabocins to treat the …See details»
Mutabilis Company Profile - Office Locations, Competitors ... - Craft
The company develops chemical entities, from biological targets to the end of Phase I, to treat MDR Gram-negative bacterial infections. See insights on Mutabilis including office locations, …See details»
Mutabilis - Carb-X
Sep 1, 2020 · Mutabilis is developing new intravenous drug, EBL-1463, a novel class of non-beta-lactam inhibitor of penicillin binding proteins (PBPs) called dabocins, to treat infections caused …See details»
Mutabilis’ EBL-1463 programme graduates from ENABLE with
French biopharmaceutical Mutabilis has identified a lead development candidate in its EBL-1463 program, which recently was awarded funding from CARB-X. The lead candidate was …See details»
Mutabilis | VentureRadar
Website: http://www.mutabilis.fr/ Based in Seine-Saint-Denis, next to Paris, Mutabilis is a biopharmaceutical company focusing on the development of breakthrough anti infective …See details»
Mutabilis - Products, Competitors, Financials, Employees, …
Mutabilis is a biopharmaceutical company focused on the development of novel-class antibacterials for the treatment of life-threatening infections caused by critical pathogens. Use …See details»
Mutabilis joins European ENABLE project to develop new antibiotics
Oct 18, 2017 · Mutabilis has been selected by the European Gram-negative antibacterial engine (ENABLE) project to focus on the improved development of antibiotics against infections …See details»
Novo Holdings REPAIR Impact Fund Invests USD 12 million in …
Today, the Novo Holdings REPAIR Impact Fund announced a EUR 7 [USD 8] million investment in Mutabilis, a company developing novel antibacterials against Gram-negative infections …See details»
Mutabilis CEO and Key Executive Team | Craft.co
Mutabilis's CSO is François Moreau. Other executives include Sophie Chasset, Director of Chemistry; Wandrille RACT MADOUX, CEO. See the full leadership team at Craft.See details»
Top 21 Stellar Biotechnology Enterprises in France - Inven
16. Mutabilis. Website: mutabilis.fr; Headquarters: Romainville, Île-De-France, France; Headcount: 11-50; LinkedIn; Mutabilis is a biopharmaceutical company specialized in research …See details»
☑️Mutabilis — Consulting Organization from France, experience …
Mutabilis — Consulting Organization from France, has experience with The Seventh Framework Programme, it`s involved in Health, Science & Innovation sectorsSee details»
Lupinus mutabilis - Wikipedia
Lupinus mutabilis is a species of lupin grown in the Andes, mainly for its edible bean.Vernacular names include tarwi (in Quechua II, [2] pronounced tarhui), chocho, altramuz, Andean lupin, …See details»